Pharma Marketing Owns Awareness. So Why Doesn't It Own the Outcome?
Pharma marketing measurement has become precise at the front of the journey. Verified HCP audiences, programmatic delivery across specialist publisher networks, point-of-care placements inside clinical workflows — the infrastructure for measuring physician reach is sophisticated and well-funded. What the industry has not built with the same rigour is accountability for what happens next.
The gap between a physician seeing a message and a patient filling a prescription is where pharma marketing's responsibility has historically ended. The data argues that this needs to change.
Where Pharma Marketing Measurement Stops
What the current metrics answer (and what they don't)
They do not answer whether those physicians prescribed the therapy, whether those prescriptions reached the pharmacy, or whether patients stayed on treatment long enough to benefit. Pharma marketing has defined its job as awareness generation and built its measurement infrastructure accordingly.
That definition has a cost. According to a November 2025 analysis by Diaceutics, 26% of pharma marketers cite measuring campaign effectiveness as their top challenge, particularly when it comes to linking spend to therapy adoption. Meanwhile, by 2026, nearly 4 in 5 pharma promotional dollars will flow to digital channels - a 14% increase from 2023, according to IQVIA research published in December 2025 citing eMarketer. Spend is scaling. Accountability is not keeping pace.
The Patient Cost of the Measurement Gap
Half of novel specialty prescriptions go unfilled
April 2026 IQVIA data, reported by Specialty Pharmacy Continuum, found that half of novel specialty prescriptions go unfilled.
A physician reached by a campaign who writes a prescription has not yet delivered the outcome the brand was designed to create.
Up to 50% of chronic disease patients don't adhere
A June 2025 analysis by PharmD Live, drawing on National Community Pharmacists Association data and WHO adherence research, found that up to 50% of patients with chronic conditions do not take their medications as prescribed.
A December 2025 peer-reviewed study published in Frontiers in Pharmacology on adherence in chronic disease populations reinforces this finding.
A filled prescription that goes untaken delivers no clinical value. These numbers do not appear in a standard pharma marketing performance review. They should.
Why the Gap Is Structural
The prescription journey cuts across multiple functions: brand marketing, field force, patient services, and pharmacy networks, each with its own KPIs, its own agency relationships, and its own definition of where its remit ends. No single function owns the full journey.
Attribution across that full journey compounds the problem. As IQVIA's December 2025 analysis notes, the challenge is not accessing data - it is unlocking its full potential: breaking down silos, accelerating reporting, and connecting ROI signals quickly enough to inform timely decisions.
The industry has also benchmarked itself against itself. Reach among target specialties and impression delivery are relative metrics. They tell you how you performed compared to the prior campaign. They do not tell you whether a patient received the treatment their physician intended to prescribe.
What Outcome Measurement Actually Requires
Closing this gap does not mean pharma marketing absorbs functions it does not own. It means extending visibility further along the journey than the current model permits.
1. Connected data across the prescription journey.
Media data, prescribing data, and patient support data need to communicate with each other. A unified view of the journey, from the first physician touchpoint to pharmacy fill, makes the gap visible in a way that siloed measurement cannot. Doceree's AI-powered healthcare marketing platform is built around this connection, unifying media exposure, NPI-matched prescribing data, and patient journey signals on a single operating system so brand teams can measure from first impression to filled prescription.
2. Metrics tied to therapy outcomes.
Therapy start rate, prescription fill rate, and days on therapy are not exotic measurements. They are the outputs that determine whether a brand is generating clinical value, not just awareness. Marketing should be held closer to those metrics.
3. Engagement timed to physician decision moments.
A physician who becomes aware of a therapy is at the beginning of a decision process. Marketing that follows that physician through the clinical decision, with relevant, timely information at the moments when prescribing decisions are made, is more likely to produce the outcome that follows.
This Is No Longer a Technology Problem
The infrastructure to unify the prescription journey now exists. What has not kept pace is the organisational willingness to use it, to hold the marketing function accountable for outcomes that happen downstream of the impression.A marketing function that can demonstrate its contribution to therapy starts, prescription fill, and patient adherence holds a fundamentally different position in a business conversation than one that reports reach and frequency. Owning the outcome is the logical completion of pharma marketing's existing remit.
Ready to connect your campaign data to the full prescription journey? Talk to Doceree: doceree.com
About Doceree
Doceree is the world's first AI-powered operating system for healthcare marketing, founded in 2020 and headquartered in Short Hills, New Jersey. Its platform integrates with 150+ EHR systems and serves pharma manufacturers, media agencies, and healthcare publishers across the prescription journey.
Frequently Asked Questions
What does outcome-focused pharma marketing measurement mean?
Outcome-focused pharma marketing measurement extends accountability beyond physician awareness to include whether campaigns influence prescribing behaviour, whether prescriptions reach the pharmacy, and whether patients adhere to therapy. It connects media performance data to clinical and dispensing data, rather than stopping at impressions.
Why has pharma marketing traditionally focused on awareness metrics?
Pharma marketing's focus on awareness metrics developed because those metrics are channel-native and technically easier to produce. As IQVIA's December 2025 analysis notes, connecting media data to prescribing and adherence data requires cross-functional integration and breaking down silos that have historically operated under separate success criteria.
What percentage of specialty prescriptions go unfilled?
According to April 2026 IQVIA data reported by Specialty Pharmacy Continuum, half of novel specialty prescriptions go unfilled. For pharma marketers, that gap between physician intent and patient access is partly addressable through better-timed affordability and access messaging at the point of prescribing.
How does a siloed pharma marketing structure affect patient outcomes?
When brand marketing, field force, and patient services each operate under separate KPIs with no shared view of the prescription journey, no function is accountable for the end-to-end result. Diaceutics found that 26% of pharma marketers name measuring cross-channel effectiveness as their top challenge — precisely because the data infrastructure to link spend to therapy adoption is fragmented across functions.
What metrics should pharma brand teams track beyond reach and frequency?
Beyond reach and frequency, pharma brand teams should track therapy start rate, prescription fill rate, and days on therapy. These outputs determine whether a brand generates real clinical and commercial value, not just physician awareness.
What is the difference between pharma marketing responsibility and accountability?
Responsibility means owning the actions that influence an outcome. Accountability means being measured against it. Pharma marketing currently holds responsibility for awareness without being measured for what follows. Extending accountability to prescription and adherence outcomes does not require the function to own every step — it requires shared visibility across the full journey.
How widespread is the medication adherence problem among chronic disease patients?
A June 2025 analysis by PharmD Live, citing NCPA and WHO adherence research, found that up to 50% of patients with chronic conditions do not take their medications as prescribed. A December 2025 peer-reviewed study in Frontiers in Pharmacology examining chronic disease populations corroborates this finding.